Migraine prevention review reports benefits, with uneven evidence across treatments
A network meta-analysis reported benefits for several oral medicines, but some findings came from limited evidence or individual studies.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reported statistically significant preventive effects for topiramate, valproate and propranolol, while several other options showed possible benefits. Some combinations were reported to perform better than single treatments. However, the abstract does not provide the numerical comparisons needed to judge benefit size, rank treatments reliably or balance benefits against specific harms.
The abstract provides no treatment effect estimates, confidence intervals or follow-up lengths. It describes limited evidence for quality-of-life gains and single-study findings for some drugs, which restrict confidence in broad treatment comparisons.
What prevention meant
The main outcome was the number of migraine attacks per month. Researchers also examined response rates, attack duration, pain intensity, quality of life and adverse events, so reported benefits concerned several different outcomes.
Where uncertainty was greatest
Quality-of-life results rested on limited evidence, while findings for valsartan and a-dihydroergocryptine largely came from individual studies. Combinations were reported to have fewer adverse events than single treatments, but the abstract gives no estimates to assess that safety comparison.
The original publication
Oral preventive medications for migraine in adults aged 18-65: a network meta-analysis.
Wu J, Wu J, Zhang J et al.
Front Pharmacol · 2025
- PubMed ID
- 40978493
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.